Orthocell Investor Centre
Orthocell is a publicly-traded company listed on the Australian Securities Exchange (ASX:OCC).
Fully funded with the required funds for the investments necessary to fund ongoing US commercialisation and other regulatory initiatives to reach profitability.
GMP-certified and TGA-licensed manufacturing facility with manufacturing scale-up programs underway to meet strategic growth opportunities.
Accelerating global commercial traction with US strategy on-track, strategic Asian expansion focused on high-return markets, and UK/EU launch planning underway.
Highly experienced board and management team that has recruited specialist talent to deepen and enable scalable growth.
. To view a full summary of the Company’s current performance on the ASX click here
“Our Company is pursuing a total addressable market for our dental, nerve and autologous tendon therapy products of US$17.7 billion per annum – a compelling investment and growth opportunity.”
Orthocell MD, Paul Anderson
Latest news
Replay | Q4 FY26 Results Webinar
Orthocell has released the replay of its July investor webinar, in which Chair John Van Der Wielen, CEO and Managing Director Paul Anderson, CFO Jim Piper and VP U.S. Sales John Walker set out the strategy behind the Company’s record FY2026 results and the momentum building in its U.S. commercialisation of Remplir™. Insights from the webinar include: A foundation-first…
Orthocell delivers record quarterly and full-year revenue as global commercial momentum accelerates
Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 30 June 2026, reporting record quarterly and full-year revenue, continued growth in the United States and further expansion across international markets. Key highlights from this quarter include: Orthocell delivered record quarterly revenue of $3.8 million, representing a 20% increase on the March quarter and a 36% increase…
Orthocell Appoints Exclusive Remplir™ Distributor for Thailand
Orthocell Limited (ASX: OCC) has appointed medical device distributor MediTime as its exclusive distributor for Remplir™ in Thailand, following regulatory approval from the Thai Food and Drug Administration to commence sales into an estimated US$84 million nerve repair market. MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across Thailand’s leading hospitals, medical schools and regional centres, and a…